← Search & browse all drugs
NERVOUS SYSTEM › PSYCHOLEPTICS › ANTIPSYCHOTICS › Phenothiazines with piperazine structure
thioproperazine
N05AB08
Forms & Strengths
- Oral tablets: 10 mg
- Solution for injection: 10 mg/mL
Adult Dosing
- Initial: 10 to 20 mg daily in divided doses
- Maintenance: 5 to 40 mg daily depending on clinical response
- Maximum daily dose: 90 mg in severe cases
Pediatric Dosing
- Not recommended for children under 15 years due to high potency and severe extrapyramidal risk
Indications
- Acute and chronic schizophrenia
- Severe treatment-refractory psychotic disorders
- Manic phases of bipolar disorder
Mechanism of Action
- High-affinity antagonist at central dopamine D2 and D3 receptors in the mesolimbic and nigrostriatal pathways
- Moderate antagonism at alpha-1 adrenergic, muscarinic (M1), and histamine (H1) receptors
Contraindications
- Known hypersensitivity to phenothiazines
- Severe central nervous system depression or comatose states
- Circulatory collapse and bone marrow depression
- Risk of closed-angle glaucoma and urinary retention related to prostatic enlargement
Adverse Reactions
- High incidence of extrapyramidal symptoms including acute dystonia, akathisia, and parkinsonism
- Tardive dyskinesia with long-term use
- Sedation, dizziness, and orthostatic hypotension
- Anticholinergic effects including dry mouth, constipation, and blurred vision
- Rare risk of neuroleptic malignant syndrome
Drug Interactions
- Potentiation of CNS depression with alcohol, opioids, sedatives, and hypnotics
- Enhanced anticholinergic toxicity when combined with drugs having antimuscarinic properties
- Increased risk of QT prolongation and arrhythmias with other QT-prolonging agents
- Antagonism of the therapeutic effects of levodopa and other dopaminergic agonists
Curated Content: Needs Vetting Before Put to Clinical Use